A new therapeutic target for metastatic and resistant prostate cancers

December 6, 2018, IDIBELL-Bellvitge Biomedical Research Institute
Álvaro Aytés & Katia Ruggero. Credit: IDIBELL

Prostate Cancer researchers from the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Álvaro Aytés report a new combined therapy to fight the most aggressive and resistant prostate cancers. The team, which has just published its results in Nature Communications, also includes researchers from the Catalan Institute of Oncology, Columbia University in New York and the University of Bern in Switzerland.

The study identifies a new vulnerability in aggressive, metastatic cancers that have become resistant to the hormonal therapies. Specifically, they showed that these tumors generate increasing levels of the NSD2 protein during progression and acquisition of resistance to therapies. In addition, they experimentally confirmed that these tumors are dependent on this protein in order to keep growing and spreading. For these reasons, NSD2 represents an emerging therapeutic target against prostate cancer.

To achieve these results, the researchers used a series of transgenic mice carrying mutations that are prevalent in prostate cancer patients. These mutations were only active in the cells of the prostatic epithelium, as happens in the vast majority of human patients. Based on these models, once the mice developed cancer, cells from both primary prostate tumors and metastases were isolated, and patterns of gene expression were analyzed. Via bioinformatics tools, the researchers identified candidate genes to be regarded as vulnerabilities in these aggressive tumors. Following this experimental approach, the team identified those factors that, in a differential way, are present in malignancy and metastasis. NSD2 is one of the main examples.

NSD2 is a protein with that induces chemical modifications (specifically, ) to other proteins in charge of providing structural support to DNA strands, called histones. This process of chemical modification of DNA, or epigenetics, is often associated with the control of gene expression. Specifically, the modifications in histones caused by NSD2 result in a relaxation in the levels of compaction of the DNA strands (known as chromatin), triggering the expression of a set of genes with tumorigenic potential.

One of the main hypotheses of the researchers behind this study is that the NSD2-caused activation of these genes is responsible for the development of resistance to the chemotherapeutic treatments usually administered to prostate patients. The researchers are working with molecules capable of inhibiting the function of NSD2 and, therefore, decreasing the malignancy of prostate tumors in mice. In fact, the study has shown that the pharmacological inhibition of NSD2 results in an increase in the survival of the experimental model, a decrease in metastasis and a reduction in the size of the tumors.

The researchers conclude that the inhibition of NSD2 could lead to re-sensitization of prostate tumors that show resistance to the usual antiandrogenic treatments. This may eventually lead to the implementation of a combined therapy that would include the administration of an NSD2 inhibitor drug together with conventional antiandrogenic drugs.

Explore further: When one drug fails, a new door opens for cancer treatment

More information: Alvaro Aytes et al. NSD2 is a conserved driver of metastatic prostate cancer progression, Nature Communications (2018). DOI: 10.1038/s41467-018-07511-4

Related Stories

When one drug fails, a new door opens for cancer treatment

June 26, 2018
A new class of cancer drugs—called CDK4/6 inhibitors—recently approved to treat breast cancer can stunt the cancer's growth and replication. It is also being explored for a number of other cancers. Unfortunately, patients ...

Discovering the mechanisms that underlie prostate cancer

July 12, 2018
New research has uncovered insights into the mechanisms that underlie prostate cancer, providing potential targets for new cancer therapies.

Tumors grown in the lab provide insights on rare prostate cancer

July 4, 2018
Growing miniature tumors from patient's cells in the laboratory may help scientists personalize treatments for those with a rare form of prostate cancer, according a study by Weill Cornell Medicine and NewYork-Presbyterian ...

Cancer researchers identify new metastasis suppressor gene

July 14, 2014
(Medical Xpress)—Among patients with deadly cancers, more than 90 percent die because of metastatic spread of their disease. Looking to target a key pathway in order to interfere with the processes that lead to tumor spread, ...

Genes may cause tumor aggressiveness and drug resistance in African-American prostate cancer

June 30, 2017
A form of genetic variation, called differential RNA splicing, may have a role in tumor aggressiveness and drug resistance in African American men with prostate cancer. Researchers at the George Washington University (GW) ...

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

Scientists identify method to study resilience to pain

December 14, 2018
Scientists at the Yale School of Medicine and Veterans Affairs Connecticut Healthcare System have successfully demonstrated that it is possible to pinpoint genes that contribute to inter-individual differences in pain.

CRISPR joins battle of the bulge, fights obesity without edits to genome

December 13, 2018
A weighty new study shows that CRISPR therapies can cut fat without cutting DNA. In a paper published Dec. 13, 2018, in the journal Science, UC San Francisco researchers describe how a modified version of CRISPR was used ...

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Noncoding mutations contribute to autism risk

December 13, 2018
A whole-genome sequencing study of nearly 2,000 families has implicated mutations in 'promoter regions' of the genome—regions that precede the start of a gene—in autism. The study, which appears in the December 14 issue ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.